Bluejay's IL-6 Sepsis Test Data to Debut at 2026 SAEM Meeting

Event summary

  • Bluejay's abstract on its Symphony™ IL-6 Test accepted for 2026 SAEM Annual Meeting (May 18–21, Atlanta).
  • Presentation details SYMON-I study results linking IL-6 levels in sepsis patients to organ dysfunction.
  • SYMON-II pivotal study underway to validate findings for potential FDA 510(k) submission.
  • Symphony™ IL-6 Test aims for 20-minute sample-to-result sepsis triage.

The big picture

Bluejay's presentation at SAEM underscores the growing emphasis on biomarkers for early sepsis intervention. The company's Symphony™ platform competes in a space where rapid diagnostics could reduce ICU mortality rates and healthcare costs. Success hinges on regulatory clearance and proving clinical utility in real-world settings.

What we're watching

Regulatory Pathway
Whether SYMON-II data will support a successful 510(k) submission for the IL-6 Test.
Clinical Validation
How SYMON-III study results may expand the IL-6 Test's utility beyond sepsis.
Market Adoption
The pace at which emergency departments might integrate rapid IL-6 testing into sepsis protocols.